Model Name
Klebsiella pneumoniae (ATCC 43816), Peritonitis, LD90-100

Item Number
608540

Introduction
This model assesses the efficacy of test articles at protecting against a lethal peritonitis infection. The procedure can be used to evaluate small molecules, vaccines and biologics. Klebsiella pneumoniae is a commensal Gram-negative bacterium that can cause life-threatening infections such as bacteremia, peritonitis, lung, and urinary tract infections. This mouse virulent strain is commonly reported in literature for the evaluation of antimicrobial agents.

Procedure Summary
Groups of 10 immune competent mice are used. Each animal is inoculated with an intraperitoneally administered LD90-100 dose of pathogen with 5% mucin. Test substance and vehicle are administered one hour later. Doses may be administered IV, SC, PO, IM, IP or by IV infusion. Mortality is recorded daily during the following 7 days. Prevention of mortality in 50 percent or more (>50%) of the animals indicates significant activity. The Minimum Effective Dose (MED) is defined as the dose that results in survival of 50% (or more) of the test animals.

Turnaround Time(s)
6 weeks from sample receipt

Literature

Optional Services
Cytokine analysis, with Luminex, can be performed upon request.

Related Assay(s)  (Item # - Assay Name - Species)
612200* - Klebsiella pneumoniae (ATCC 43816) MIC - Bacteria
608550 - Klebsiella pneumoniae (ATCC 43816), Lung Infection Model, CFU/g - Mouse
608570 - Klebsiella pneumoniae (ATCC 43816), Thigh Infection Model, CFU/g - Mouse
608575 - Klebsiella pneumoniae (ATCC 43816), Thigh Infection Model, Rat, CFU/g - Rat
*provided by partner lab Eurofins Pharma Discovery Services

Modified Protocols
We will readily accommodate client-specified alterations.

Laboratory
These assays are performed at our AAALAC accredited BSL2 laboratory in Taipei, Taiwan.

Animal Welfare
All aspects of this work is performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

Reference Compound(s)
Colistin, Levofloxacin

For current details about our Company address and contact information, please reference our website http://www.pharmacologydiscoveryservices.com/company-info/
Graph(s)

**608540 Klebsiella pneumoniae (ATCC 43816)**

**Peritonitis, LD$_{90-100}$**

**Levofloxacin (LVX) efficacy**

![Graph](image)

**Days after infection**

- Vehicle (IV)
- LVX 30 mg/kg (IV)
- LVX 10 mg/kg (IV)
- LVX 3 mg/kg (IV)

**608540 Klebsiella pneumoniae (ATCC 43816)**

**Peritonitis, LD$_{90-100}$**

**Colistin (CST) efficacy**

![Graph](image)

**Days after infection**

- Vehicle (SC)
- CST 30 mg/kg (SC)
- CST 10 mg/kg (SC)
- CST 3 mg/kg (SC)
- CST 1 mg/kg (SC)

Last modified November 20, 2017

For current details about our Company address and contact information, please reference our website [http://www.pharmacologydiscoveryservices.com/company-info/](http://www.pharmacologydiscoveryservices.com/company-info/)